Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 401–500 of 1,016
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Acar, A., Nichol, D., Fernández-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15596-z · Cited by 153
Machine learning methods, databases and tools for drug combination prediction
Wu, L., Wen, Y., Leng, D., Zhang, Q., Dai, C., Wang, Z., Liu, Z., Yan, B., Zhang, Y., Wang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab355 · Cited by 126
Singh, N., Kim, J., Kim, J., Lee, K., Zunbul, Z., Lee, I., Kim, E., Chi, S.-G., & Kim, J. S. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.08.016 · Cited by 179
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 147
“Equation (11) represents the metastasis rate regulated by DIRF concentration with λ K being a Michaelis constant.”
Abd-Ellatef, G. E. F., Gazzano, E., Chirio, D., Hamed, A. R., Belisario, D. C., Zuddas, C., Peira, E., Rolando, B., Kopecka, J., Marie, M. A. S., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020096 · Cited by 136
“It has already been reported that CURC down-regulates Pgp expression by reducing Akt/NF-kB activation [2].”
BackgroundShen, J., Karges, J., Xiong, K., Chen, Y., Ji, L., & Chao, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120979 · Cited by 130
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Jiang, H., Liu, X., Knolhoff, B. L., Hegde, S., Lee, K. B., Jiang, H., Fields, R. C., Pachter, J. A., Lim, K.-H., & DeNardo, D. G. (2020) · Gut · doi:10.1136/gutjnl-2018-317424 · Cited by 130
He, C., Liu, D., & Lin, W. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.09.017 · Cited by 129
Tsouris, V., Joo, M. K., Kim, S. H., Kwon, I. C., & Won, Y. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.05.006 · Cited by 135
CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
Lü, S., Yao, Y., Xu, G., Chao Hui, Z. H. O. U., Zhang, Y., Sun, J., Jiang, R., Shao, Q., & Chen, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0681-z · Cited by 138
Wu, W., Chen, M., Luo, T., Fan, Y., Zhang, J., Zhang, J., Zhang, Q., Sapin‐Minet, A., Gaucher, C., & Xia, X. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.12.016 · Cited by 131
Zhang, Q., Kuang, G., He, S., Lu, H., Cheng, Y., Zhou, D., & Huang, Y. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04981 · Cited by 131
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 131
Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer
Lu, L., Zhang, Y., Tan, X., Merkher, Y., Leonov, S. V., Zhu, L., Deng, Y., zhang, H., Zhu, D., Tan, Y., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01101-6 · Cited by 145
“Apoptosis is considered the primary form of chemotherapeutic drug-induced tumour cell death [113].”
BackgroundLi, Y., Xu, X., Zhang, X., Li, Y., Zhang, Z., & Gu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.6b06161 · Cited by 127
Li, X., Xu, Y., Cui, H. S., Huang, T., Wang, D., Lian, B., Li, W., Qin, G., Chen, L., & Xie, L. (2017) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2017.05.008 · Cited by 141
“Drug resistance and side effect have been considered as the main reasons for the failure of cancer chemotherapy [2,3].”
BackgroundGlycogen Synthase Kinase 3β in Cancer Biology and Treatment
Domoto, T., Uehara, M., Bolidong, D., & Minamoto, T. (2020) · Cells · doi:10.3390/cells9061388 · Cited by 151
Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy
Strobl, M. A. R., West, J., Viossat, Y., Damaghi, M., Robertson‐Tessi, M., Brown, J. S., Gatenby, R. A., Maini, P. K., & Anderson, A. R. A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0806 · Cited by 149
Chen, S., Yang, K., Tuguntaev, R. G., Mozhi, A., Zhang, J., Wang, P. C., & Liang, X.-J. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.020 · Cited by 126
Caveolin‐1, cancer and therapy resistance
Ketteler, J., & Klein, D. (2018) · International Journal of Cancer · doi:10.1002/ijc.31369 · Cited by 126
A potential carrier for anti-tumor targeted delivery-hyaluronic acid nanoparticles
Cai, J., Fu, J., Li, R., Zhang, F., Ling, G., & Zhang, P. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.12.074 · Cited by 130
Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine
Zhang, M., Chen, X., Li, C., & Shen, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.024 · Cited by 126
Wang, L., Yu, Y., Wei, D., Zhang, L., Zhang, X., Zhang, G., Ding, D., Xiao, H., & Zhang, D. (2021) · Advanced Materials · doi:10.1002/adma.202100599 · Cited by 129
Fu, F., Nowak, M. A., & Bonhoeffer, S. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004142 · Cited by 126
“The recurrence of cancer, if trea ted with single agents, is almost certain due to acquired drug resistance [12, 13].”
BackgroundXu, R. F., Yang, J., Qian, Y., Deng, H., Wang, Z., Ma, S., Wei, Y., Yang, N., & Shen, Q. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00674b · Cited by 126
Integration of phytochemicals and phytotherapy into cancer precision medicine
Efferth, T., Saeed, M. E. M., Mirghani, E., Alim, A., Yassin, Z., Saeed, E. M., Khalid, H. E., & Daak, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17466 · Cited by 143
Hekmatshoar, Y., Nakhle, J., Galloni, M., & Vignais, M. (2018) · Biochemical Journal · doi:10.1042/bcj20170712 · Cited by 132
Metformin in breast cancer: preclinical and clinical evidence
De, A., & Kuppusamy, G. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.06.003 · Cited by 124
Luan, F., He, X., & Zeng, N. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13339 · Cited by 124
“The cell cycle is an appropriately controlled progression of the growth, differentiation and proliferation of eukaryotic cells([117]) and is an essential process required for the normal growth and maintenance of a healthy cell.([118,119]) Tetrandrine acts as a checkpoint inhibitor of the cell cycle in cancer cells and…”
BackgroundThe within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy
Trauner, A., Liu, Q., Via, L. E., Liu, X., Ruan, X., Liang, L., Shi, H., Chen, Y., Wang, Z., Liang, R., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1196-0 · Cited by 138
ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM
Zhang, X., Zhang, Z., Zhang, Q., Zhang, Q., Sun, P., Xiang, R., Ren, G., & Yang, S. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0087-3 · Cited by 119
Drug metabolizing enzymes and their inhibitors' role in cancer resistance
Pathania, S., Bhatia, R., Baldi, A., Singh, R., & Rawal, R. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.117 · Cited by 136
CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression
Wang, Z., Zhao, K., Hackert, T., & Zöller, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00097 · Cited by 135
“CIC and Apoptosis Resistance Poor prognosis of patients with disseminated cancer relies in part on CIC resistance toward conventional chemo- and radiation therapy (Holohan et al., 2013; Di and Zhao, 2015; Mansoori et al., 2017).”
BackgroundChen, X., Li, Y., Li, S., Gao, M., Ren, L., & Tang, B. Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804362 · Cited by 123
Advances and applications of nanoparticles in cancer therapy
Huang, X., He, T., Liang, X., Xiang, Z., Liu, C., Zhou, S., Luo, R., Bai, L., Kou, X., Li, X., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.67 · Cited by 156
Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach
Ruderfer, D. M., Charney, A. W., Readhead, B., Kidd, B. A., Kähler, A. K., Kenny, P. J., Keiser, M. J., Moran, J. L., Hultman, C. M., Scott, S. A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00553-2 · Cited by 126
Tong, Y., Liu, Y., Zheng, H., Zheng, L., Liu, W., Wu, J., Ou, R., Zhang, G., Li, F., Hu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8920 · Cited by 130
“However, drug resistance, subsequent metastasis, and accumulated toxicity to normal cell and immune system limit the clinical benefit of chemotherapies and the median survival to 1 year [4, 5].”
BackgroundNanoceria-Mediated Drug Delivery for Targeted Photodynamic Therapy on Drug-Resistant Breast Cancer
Li, H., Liu, C., Zeng, Y.-P., Hao, Y., Huang, J., Yang, Z., & Li, R. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b07338 · Cited by 125
Wang, S., Yang, L., Cho, H.-Y., Dean Chueng, S.-T., Zhang, H., Zhang, Q., & Lee, K.-B. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119498 · Cited by 125
CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer
Selvakumar, S. C., Preethi, K. A., Ross, K., Tusubira, D., Khan, M. W. A., Mani, P., Rao, T. N., & Sekar, D. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01565-1 · Cited by 139
“signal transduction pathway that mediates drug activation, in addition to alterations in specific drug targets [19, 20].”
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
DNA origami/gold nanorod hybrid nanostructures for the circumvention of drug resistance
Song, L., Jiang, Q., Liu, J., Li, N., Liu, Q. L., Dai, L., Gao, Y., Liu, W., Liu, D., & Ding, B. (2017) · Nanoscale · doi:10.1039/c7nr02222k · Cited by 123
Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance
Chen, F., Long, Q., Fu, D., Zhu, D., Ji, Y., Han, L., Zhang, B., Xu, Q., Liu, B., Li, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06860-4 · Cited by 122
Molecular mechanism of palmitic acid and its derivatives in tumor progression
Wang, X., Zhang, C., & Bao, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1224125 · Cited by 155
Intratumoral heterogeneity and drug resistance in cancer
Fu, Y.-C., Liang, S.-B., Luo, M., & Wang, X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03734-w · Cited by 148
“For instance, tumor cells in proximity to stromal cells exhibit significantly greater proliferation and survival, a phenomenon attributed to the paracrine effects of immune cells and fibroblasts [75, 78].”
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
Nelson, A., Lukacs, J., & Johnston, B. (2021) · Cancers · doi:10.3390/cancers13205174 · Cited by 133
Cheng, H., Wu, Z., Wu, C., Wang, X., Liow, S. S., Li, Z., & Wu, Y.-L. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.08.075 · Cited by 119
Tan, Q., Wang, H., Hu, Y., Hu, M., Li, X., Aodengqimuge, Ma, Y.-F., Wei, C., & Song, L. (2015) · Cancer Science · doi:10.1111/cas.12712 · Cited by 128
Mallick, A., More, P., Ghosh, S., Chippalkatti, R., Chopade, B. A., Lahiri, M., & Basu, S. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am5090226 · Cited by 119
Predictive approaches for drug combination discovery in cancer
Madani Tonekaboni, S. A., Soltan Ghoraie, L., Manem, V. S. K., & Haibe-Kains, B. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 115
Layek, B., Sadhukha, T., Panyam, J., & Prabha, S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0682 · Cited by 126
“Overexpression of drug efflux transporters such as P-glycoprotein (21, 39) in these cells further limits the loading of anticancer drugs, many of which are substrates for efflux transporters (40).”
BackgroundTumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment
Qu, Y., Dou, B., Tan, H., Feng, Y., Wang, N., & Wang, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0992-4 · Cited by 126
Zhu, L., Guo, Y., Qian, Q., Yan, D., Li, Y., Zhu, X., & Zhang, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006895 · Cited by 123
Targeting regulated cell death in tumor nanomedicines
Zeng, Q., Ma, X., Song, Y., Chen, Q., Jiao, Q., & Zhou, L. (2021) · Theranostics · doi:10.7150/thno.67932 · Cited by 125
“To enable smooth growth, cancer cells frequently display an improved iron demand, and this iron dependency will make cancer cells more vulnerable to ferroptosis [17, 18].”
BackgroundAn Overview on Gold Nanorods as Versatile Nanoparticles in Cancer Therapy
Nejabat, M., Samie, A., Ramezani, M., Alibolandi, M., Abnous, K., & Taghdisi, S. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.009 · Cited by 122
Thermo-sensitive polypeptide hydrogel for locally sequential delivery of two-pronged antitumor drugs
Wei, L., Chen, J., Zhao, S., Ding, J., & Chen, X. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.053 · Cited by 117
Asgharzadeh, M. R., Barar, J., Pourseif, M. M., Eskandani, M., Jafari Niya, M., Mashayekhi, M. R., & Omidi, Y. (2017) · BioImpacts · doi:10.15171/bi.2017.15 · Cited by 115
Paraptosis: a unique cell death mode for targeting cancer
Hanson, S., Dharan, A., Jinsha, P. V., Pal, S., Nair, B. G., Kar, R., & Mishra, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1159409 · Cited by 143
“In the case of intrinsic resistance, the resistance mediating factors will already be present in the tumour cells, but the onset of acquired resistance will be during treatment (Holohan et al., 2013).”
BackgroundLiu, Z., Zhu, G., Getzenberg, R. H., & Veltri, R. W. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25091 · Cited by 128
“While chemotherapies are often initially effective, long-term treatment leads to drug resistance [Holohan et al., 2013].”
BackgroundCombination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115
Mei, L., Zhu, G., Qiu, L., Wu, C. S., Chen, H., Liang, H., Cansız, S., Lv, Y., Zhang, X., & Tan, W. (2015) · Nano Research · doi:10.1007/s12274-015-0841-8 · Cited by 118
Schöning, J. P., Monteiro, M., & Gu, W. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12693 · Cited by 115
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Hatlen, M. A., Schmidt-Kittler, O., Sherwin, C. A., Rozsahegyi, E., Rubin, N., Sheets, M. P., Kim, J. L., Miduturu, C., Bifulco, N., Brooijmans, N., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0367 · Cited by 112
“9 kinase inhibitors are small hydrophobic compounds that can rapidly outcompete ATP for their intracellular target, a common form of resistance has been on-target mutation within the kinase domain active site (22).”
BackgroundFinding needles in a basestack: recognition of mismatched base pairs in DNA by small molecules
Granzhan, A., Kotera, N., & Teulade‐Fichou, M. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60455a · Cited by 117
Lee, H.-J., Li, C.-F., Ruan, D., Powers, S., Thompson, P. A., Frohman, M. A., & Chan, C.-H. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.009 · Cited by 116
“In contrast, progress toward dramatic improvements in long-term survival and tumor eradication, particularly for metastatic patients, remains disappointing (Holohan et al., 2013).”
Revisiting the IGF-1R as a breast cancer target
Ekyalongo, R. C., & Yee, D. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0017-y · Cited by 114
“The complexity of the molecular mechanisms underlying these important clinical phenotypes remains a principal challenge for the development of new drugs.(78) Development of resistance promotes the acquisition of activation of other oncogenic molecules, which IGF-2R IR-A IR-B IGF-1R/IR-A IGF-1R/IR-B IGF-1R IR-A/IR-B”
BackgroundRahimi, M., Safa, K. D., & Salehi, R. (2017) · Polymer Chemistry · doi:10.1039/c7py01701d · Cited by 117
Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands?
Calderwood, S. K. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0524 · Cited by 126
Rybak, A. P., Bristow, R. G., & Kapoor, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2953 · Cited by 135
“The SP phenotype is associated with the expression of the ATP-binding cassette membrane transporter family of proteins, particularly ABCG2 [81], which are involved in drug efflux and confer multi-drug resistance [82].”
BackgroundLi, Z., Wang, H., Chen, Y., Wang, Y., Li, H., Han, H., Chen, T., Jin, Q., & Ji, J. (2016) · Small · doi:10.1002/smll.201600365 · Cited by 117
McComb, S., Aguadé-Gorgorió, J., Harder, L., Marovca, B., Cario, G., Eckert, C., Schrappe, M., Stanulla, M., von Stackelberg, A., Bourquin, J.-P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2986 · Cited by 115
β-Ionone and its analogs as promising anticancer agents
Ansari, M., & Emami, S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.037 · Cited by 116
Pan, Q., Chen, T., Nie, C., Yi, J., Liu, C., Hu, Y., & Chu, X. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b13393 · Cited by 114
Carbon nanotubes in drug delivery: Focus on anticancer therapies
Kiran, A. V. V. V. R., Kumari, G. K., & Krishnamurthy, P. T. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101892 · Cited by 114
Glycolysis-induced drug resistance in tumors—A response to danger signals?
Marcucci, F., & Rumio, C. (2021) · Neoplasia · doi:10.1016/j.neo.2020.12.009 · Cited by 124
Chen, J., Cheong, H. H., & Siu, S. W. I. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00181 · Cited by 114
Epigenetic drugs in cancer therapy
Suraweera, A., O'Byrne, K. J., & Richard, D. J. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10253-7 · Cited by 140
“Resistance to current anti-cancer treatments including chemotherapy, targeted therapies and immunotherapy are inevitable [76, 77].”
Yang, Q., Huang, J., Wu, Q., Cai, Y., Zhu, L., Lu, X., Chen, S., Chen, C., & Wang, Z. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.136 · Cited by 115
“However, intrinsic or acquired resistance to chemotherapeutic drug leads to failure of chemotherapy in many patients with breast cancer (Ali and Coombes, 2002; Holohan et al, 2013).”
BackgroundSun, Y., Zhu, D., Chen, F., Qian, M., Wei, H., Chen, W., & Xu, J. (2016) · Oncogene · doi:10.1038/onc.2015.494 · Cited by 116
“30 The protection exerted by activated TME forms a refuge for cancer cell populations including cancer stem cells against cytotoxic agents, thus enabling them to evade apoptosis and develop acquired resistance as a prerequisite for disease recurrence.”
RetractedZhang, R., Li, J., Zhang, T., Amini, M. A., He, C., Lu, B., Ahmed, T., Lip, H., Rauth, A. M., & Wu, X. Y. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.33 · Cited by 122
Liu, X., Lu, Y., Xu, Y., Hou, S., Huang, J., Wang, B., Zhao, J., Xia, S., Fan, S., Yu, X., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.035 · Cited by 113
Leon, L. M., Gautier‐Isola, M., Allan, R., Ilié, M., Nottet, N., Pons, N., Paquet, A. C., Lebrigand, K., Truchi, M., Fassy, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0935-y · Cited by 124
“Hypoxia, a condition frequently encountered in solid tumors, activates the hypoxia-inducible factor (HIF) transcription complex that orchestrates the expression of a myriad of genes, whose functions are to ensure neovascularization, glucose metabolism, cell survival, tumor spread, and resistance to most anticancer dru…”
BackgroundRole of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance
dos Santos, P. W. D. S., & Almeida, F. B. D. R. (2020) · Cells · doi:10.3390/cells9061450 · Cited by 124
“Acquired drug resistance constitutes a group of cells that emerge resistant from a population that was previously drug-sensitive, resulting in tumor regrowth [22].”
BackgroundShen, W. H., Zhang, Y., Wan, P., An, L., Zhang, P., Xiao, C., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202001108 · Cited by 113
The tumor microenvironment: shaping cancer progression and treatment response
Desai, S. A., Patel, V. P., Bhosle, K. P., Nagare, S. D., & Thombare, K. C. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2300224 · Cited by 106
Protecting the normal in order to better kill the cancer
Liu, B., Ezeogu, L., Zellmer, L., Yu, B., Xu, N., & Liao, D. J. (2015) · Cancer Medicine · doi:10.1002/cam4.488 · Cited by 113
“Compromising this alternative will induce cancercellspecific death while sparing normal cells in which this pathway is functionally redundant [63].”
BackgroundSphingolipids: Key Regulators of Apoptosis and Pivotal Players in Cancer Drug Resistance
Giussani, P., Tringali, C., Riboni, L., Viani, P., & Venerando, B. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034356 · Cited by 132
“By contrast, targeted drugs act by blocking specific survival signalling pathways that are typically triggered by kinases or growth factor receptors [61] and induce cell death by a mechanism known as “oncogenic shock”, which is an imbalance in pro-survival and pro-apoptotic signals that is caused by the inhibition of…”
BackgroundTetrandrine and cancer – An overview on the molecular approach
Bhagya, N., & Chandrashekar, K. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.116 · Cited by 114
Smart transformable nanomedicines for cancer therapy
Wang, Y., Li, S., Wang, X., Chen, Q., He, Z., Luo, C., & Sun, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120737 · Cited by 112
Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents
Turan‐Zitouni, G., Altıntop, M. D., Özdemır, A., Kaplancıklı, Z. A., Çiftçi, G. A., & Temel, H. E. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.11.002 · Cited by 111
Dakwar, G. R., Shariati, M., Willaert, W., Ceelen, W. P., Smedt, S. C. D., & Remaut, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.001 · Cited by 125
“Overcoming the resistance of cancer cells remains one of the main hurdles in cancer therapy [97].”
BackgroundShim, M. K., Moon, Y., Yang, S., Kim, J., Cho, H., Lim, S., Yoon, H. Y., Seong, J., & Kim, K. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120347 · Cited by 118
Hu, J., Yuan, I. J., Mirshahidi, S., Simental, A., Lee, S. C., & Yuan, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041950 · Cited by 130
The role of ferroptosis in breast cancer patients: a comprehensive analysis
Wu, Z., Tang, Y., Yu, H., & Li, H. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00473-5 · Cited by 128
Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance
Zhang, Y., Zhang, C., Chen, J., Liu, L., Hu, M., Li, J., & Bi, H. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b07219 · Cited by 109
Estrogen receptor mutations and their role in breast cancer progression
Alluri, P. G., Speers, C. W., & Chinnaiyan, A. M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0494-7 · Cited by 121
“While many mechanisms of drug resistance to chemotherapeutic agents such as efflux, metabolism and inactivation have been described previously, alterations within the drug target have emerged as a dominant resistance mechanism to targeted therapies [1].”
BackgroundMou, Q., Ma, Y., Ding, F., Gao, X., Yan, D., Zhu, X., & Zhang, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13875 · Cited by 109
Dissecting miRNA signature in colorectal cancer progression and metastasis
Huang, X., Zhu, X., Yu, Y., Zhu, W., Jin, L., Zhang, X., Li, S., Zou, P., Xie, C., & Cui, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.025 · Cited by 114
Advances in Stigmasterol on its anti-tumor effect and mechanism of action
Zhang, X., Wang, J., Zhu, L., Wang, X., Meng, F., Xia, L., & Zhang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1101289 · Cited by 126
Key genes and molecular mechanisms related to Paclitaxel Resistance
Alalawy, A. I. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03415-0 · Cited by 134
“Cross-resistance may depend on the genetic profile of the patient [195].”
Background
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.